SAB Biotherapeutics, Inc. (SABS)

US — Healthcare Sector
Peers:   CMRA  PCSA  FRTX  THRD  CINGW  ANEB  CVKD  MNPR  UNCY  QNRX  CDIO  VRAX  PXMD 

Automate Your Wheel Strategy on SABS

With Tiblio's Option Bot, you can configure your own wheel strategy including SABS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SABS
  • Rev/Share 0.0407
  • Book/Share 2.304
  • PB 0.7769
  • Debt/Equity 0.3169
  • CurrentRatio 1.6882
  • ROIC -1.4315

 

  • MktCap 16632143.0
  • FreeCF/Share -3.4026
  • PFCF -0.5261
  • PE -0.4852
  • Debt/Assets 0.1779
  • DivYield 0
  • ROE -1.0514

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed SABS H.C. Wainwright -- Buy -- $10 May 14, 2025
Initiation SABS Craig Hallum -- Buy -- $11 Oct. 9, 2024
Initiation SABS Oppenheimer -- Outperform -- $12 Aug. 28, 2024

News

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
SABS
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral

MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments. Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this quarter on our corporate strategy and mission to deliver a transformational therapy that can halt or delay the progression of type 1 diabetes.

Read More
image for news SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

About SAB Biotherapeutics, Inc. (SABS)

  • IPO Date 2021-02-09
  • Website https://www.sabbiotherapeutics.com
  • Industry Biotechnology
  • CEO Mr. Samuel J. Reich
  • Employees 63
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.